次世代定序全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球次世代定序市場預計將從2025年的129.6億美元成長至2034年的419.1億美元，2026年至2034年的複合年成長率（CAGR）為13.93%。隨著基因測序在研究、臨床診斷、精準醫療、藥物研發和生物技術領域的重要性日益凸顯，該市場正在不斷擴張。與許多傳統定序方法相比，次世代定序能夠更有效率地分析海量的遺傳資訊。人們對闡明疾病機制和識別基因變異的興趣日益濃厚，推動了這項技術在醫學和生命科學領域的應用。據美國國家人類基因組研究所（NHGRI）稱，次世代定序技術使研究人員能夠以更快的速度、更大的規模對DNA定序，從而徹底改變了基因組研究。這項技術進步正在為日益多元化的基因組應用創造新的機會。

次世代定序市場的發展動力源自於定序準確性、通量、自動化程度、生物資訊學和樣本製備技術的進步。研究人員和醫療保健專業人員擴大利用定序來研究遺傳疾病、癌症相關突變、感染疾病和其他生物學疾病。定序在藥物研發領域也日益重要，基因組資訊有助於發現生物標記和進行病患分層。基於雲端的分析和先進的運算工具使得處理和解讀大規模定序資料集變得更加便捷。隨著定序工作流程的日益整合，供應商正致力於提供涵蓋儀器、耗材、軟體、數據分析和實驗室服務的綜合解決方案。

隨著定序技術的普及和應用範圍的拓展，其前景依然強勁。精準醫療尤其有望成為重要的發展機遇，因為臨床醫生擴大利用分子資訊來制定精準的診斷和治療方案。液態生物檢體、群體基因組學、感染疾病監測和農業基因組學也具有進一步成長的潛力。定序成本的降低和工作流程的簡化有望促進小規模檢查室和醫療機構對定序技術的採用。那些將高品質定序平台與強大的生物資訊學、自動化、數據解讀和安全資訊管理相結合的公司，有望從基因組學應用的持續擴展中獲益。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分重點介紹每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供以資料為基礎的市場規模和成長模式展望，預測期為指定期間。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以預測未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球次世代定序市場：依定定序類型分類

• 市場分析、洞察與預測
• 全基因測序
• 標靶重測序
• 全EXOME定序
• RNA定序
• ChIP定序
• 從頭定序
• 甲基定序

第5章：全球次世代定序市場：依產品類型分類

• 市場分析、洞察與預測
• 裝置
• 試劑和耗材
• 服務
• 藥物發現與個人化醫療
• 基因篩檢
• 診斷
• 農業和畜牧業調查
• 其他應用（表觀基因、總體基因體學、轉錄體學）

第6章：全球次世代定序市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和醫療機構
• 學術研究機構
• 製藥和生物技術公司

第7章 全球次世代定序市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • 10x Genomics Inc
  • Agilent Technologies Inc
  • BGI Genomics Co. Ltd
  • Bio-Rad Laboratories Inc
  • Element Biosciences Inc
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc
  • Guardant Health Inc
  • Illumina Inc
  • Macrogen Inc
  • Oxford Nanopore Technologies Plc
  • Pacific Biosciences Of California Inc
  • PerkinElmer Inc
  • QIAGEN NV
  • Singular Genomics Systems Inc
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc
  • Twist Bioscience Corp
  • Ultima Genomics Inc

The global next generation sequencing market size is expected to reach USD 41.91 Billion in 2034 from USD 12.96 Billion in 2025, growing at a CAGR of 13.93% during 2026-2034.This market is expanding as genomic sequencing becomes increasingly important across research, clinical diagnostics, precision medicine, drug development, and biotechnology. Next generation sequencing allows large volumes of genetic information to be analyzed more efficiently than many traditional sequencing approaches. Growing interest in understanding disease mechanisms and identifying genetic variations is encouraging adoption across healthcare and life-science applications. According to the National Human Genome Research Institute, next generation sequencing technologies have transformed genomic research by enabling researchers to sequence DNA at much greater scale and speed. This technological progress is creating opportunities across increasingly diverse genomic applications.

The next generation sequencing market is being driven by improvements in sequencing accuracy, throughput, automation, bioinformatics, and sample preparation. Researchers and healthcare providers are increasingly using sequencing to investigate inherited disorders, cancer-related mutations, infectious diseases, and other biological conditions. Sequencing is also becoming more relevant to pharmaceutical research, where genomic information can support biomarker discovery and patient stratification. Cloud-based analysis and advanced computational tools are making large sequencing datasets easier to process and interpret. As sequencing workflows become more integrated, providers are focusing on complete solutions covering instruments, consumables, software, data analysis, and laboratory services.

Future prospects remain strong as sequencing technologies become more accessible and applications expand beyond specialized research environments. Precision medicine is expected to remain an important opportunity, particularly as clinicians increasingly use molecular information to guide selected diagnostic and treatment decisions. Liquid biopsy, population genomics, infectious-disease surveillance, and agricultural genomics can provide additional growth avenues. Lower sequencing costs and simplified workflows could broaden adoption among smaller laboratories and healthcare institutions. Companies that combine high-quality sequencing platforms with robust bioinformatics, automation, data interpretation, and secure information management are likely to benefit from the continued expansion of genomic applications.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type of Sequencing

• Whole Genome Sequencing
• Targeted Resequencing
• Whole Exome Sequencing
• RNA Sequencing
• ChIP Sequencing
• De Novo Sequencing
• Methyl Sequencing

By Product Type

• Instruments
• Reagents and Consumables
• Services

By Application

• Drug Discovery and Personalized Medicine
• Genetic Screening
• Diagnostics
• Agriculture and Animal Research
• Other Applications (Epigenomics, Metagenomics, Transcriptomics)

By End User

• Hospitals and Healthcare Institutions
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies

COMPANIES PROFILED

• 10x Genomics Inc., Agilent Technologies Inc., BGI Genomics Co. Ltd., Bio-Rad Laboratories Inc., Element Biosciences Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Fulgent Genetics Inc., Guardant Health Inc., Illumina Inc., Macrogen Inc., Oxford Nanopore Technologies Plc, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN N.V., Singular Genomics Systems Inc., SOPHiA GENETICS SA, Thermo Fisher Scientific Inc., Twist Bioscience Corp., Ultima Genomics Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY TYPE OF SEQUENCING 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Sequencing
• 4.2. Whole Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted Resequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Whole Exome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. RNA Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. ChIP Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. De Novo Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Methyl Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Reagents and Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. By Application Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Drug Discovery and Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Genetic Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Agriculture and Animal Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Other Applications (Epigenomics, Metagenomics, Transcriptomics) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals and Healthcare Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Sequencing
  • 7.2.2 By Product Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Sequencing
  • 7.3.2 By Product Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Sequencing
  • 7.4.2 By Product Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Sequencing
  • 7.5.2 By Product Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Sequencing
  • 7.6.2 By Product Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NEXT GENERATION SEQUENCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 10x Genomics Inc
  • 9.2.2 Agilent Technologies Inc
  • 9.2.3 BGI Genomics Co. Ltd
  • 9.2.4 Bio-Rad Laboratories Inc
  • 9.2.5 Element Biosciences Inc
  • 9.2.6 Eurofins Scientific SE
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Fulgent Genetics Inc
  • 9.2.9 Guardant Health Inc
  • 9.2.10 Illumina Inc
  • 9.2.11 Macrogen Inc
  • 9.2.12 Oxford Nanopore Technologies Plc
  • 9.2.13 Pacific Biosciences Of California Inc
  • 9.2.14 PerkinElmer Inc
  • 9.2.15 QIAGEN N.V
  • 9.2.16 Singular Genomics Systems Inc
  • 9.2.17 SOPHiA GENETICS SA
  • 9.2.18 Thermo Fisher Scientific Inc
  • 9.2.19 Twist Bioscience Corp
  • 9.2.20 Ultima Genomics Inc